Beyond single anti-angiogenic therapy, the combination of VEGFA neutralization and angiopoietin 2 (ANGPT2) inhibition has been shown to normalize tumor vasculature, which can improve drug delivery, increase sensitivity to radiation therapy, and enhance immune cell infiltration in TME [359–361]. This evidence concerns the gene VEGFA and neoplasm.